Growth Opportunities and Trends in the Rare Biomarkers Specimen Collection And Stabilization Market: Key Insights for 2025-2034
Get 20% off on Global Market Reports until March 31st! Use code FY25SAVE at checkout.
What fueled the previous growth in the rare biomarkers specimen collection and stabilization market?
The market size for the scarce biomarkers specimen collection and stabilization has seen impressive growth recently. Projections show its expansion from $32.01 billion in 2024 to $35.4 billion in 2025 at a compound annual growth rate (CAGR) of 10.6%. Factors contributing to this historic period growth include the human genome project, a rise in cancer research, ongoing R&D investments in the pharmaceutical industry, advancements in genomics and proteomics, as well as amelioration in data management and bioinformatics.
What will be the rare biomarkers specimen collection and stabilization market size in the future?
The rare biomarkers specimen collection and stabilization market size is expected to see rapid growth in the next few years. It will grow to $52.46 billion in 2029 at a compound annual growth rate (CAGR) of 10.3%. The growth in the forecast period can be attributed to the expansion of liquid biopsy applications, consumer awareness and demand, increasing adoption of non-invasive techniques, and biomarker discovery in rare diseases. Major trends in the forecast period include advancements in preservation technology, growth in genomic and proteomic research, the emergence of point-of-care testing, and regulatory advancements and standardization, enhanced data analytics, and AI integration.
Get your rare biomarkers specimen collection and stabilization market report here!
What main drivers are fueling expansion in the rare biomarkers specimen collection and stabilization market?
The escalating incidence of cancer is predicted to drive the expansion of the rare biomarker specimen collection and stabilization market. Cancer encompasses a range of illnesses characterized by uncontrolled growth and dissemination of abnormal cells. Environmental pollutants and lifestyle choices like smoking and poor nutrition, which exacerbate genetic vulnerabilities, are causing a surge in cancer incidence. The use of rare biomarker specimen collection and stabilization techniques in cancer incidence studies allows for more precise identification and tracking of specific types of cancer, thereby improving diagnostic and treatment methods. For example, as reported by the European Commission, a governing entity based in Europe, new cases of cancer increased to 2.74 million in 2022 in October 2023, marking a 2.3% increase from 2020. Consequently, the surging incidence of cancer is fuelling the advancement of the rare biomarker specimen collection and stabilization market.
What key areas define the segmentation of the global rare biomarkers specimen collection and stabilization market?
The rare biomarkers specimen collection and stabilization market covered in this report is segmented –
1) By Type: Circulating Cell Free Deoxyribonucleic Acid (CCFDNA), Circulating Tumor Cells (CTCs), Exosomes or Extracellular Vesicles
2) By Specimen: Serum Or Plasma, Other Specimens
3) By Application: Non-Invasive Prenatal Testing (NIPT), Oncology, Transcriptomics, Pharmacogenomics, Transplant Rejection, Population Screening, Cardiovascular Diseases, Other Applications
4) By End-User: Hospitals, Perinatal Clinics, Public Health Labs, Private Or Commercial Labs, Physician Labs, Research Institutes, Other End-Users
Subsegments:
1) By Circulating Cell Free Deoxyribonucleic Acid (CCFDNA): Plasma CCFDNA, Serum CCFDNA
2) By Circulating Tumor Cells (CTCs): CTCs In Blood, CTCs In Bone Marrow
3) By Exosomes Or Extracellular Vesicles: Exosomes From Plasma, Exosomes From Serum
Get your free sample now – explore exclusive market insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=15913&type=smp
Who are the key firms paving the way for growth in the rare biomarkers specimen collection and stabilization market?
Major companies operating in the rare biomarkers specimen collection and stabilization market are F. Hoffmann-La Roche AG, Thermo Fisher Scientific Inc., Abbott Laboratories, Merck KGaA, Becton Dickinson and Company, Eurofins Scientific SE, Agilent Technologies Inc., PerkinElmer Inc., Illumina Inc., Charles River Laboratories International Inc., Bio-Rad Laboratories Inc., Bruker Corporation, QIAGEN N.V., Miltenyi Biotec GmbH, Natera Inc., Promega Corporation, Myriad Genetics, Hamilton Company, OraSure Technologies Inc., Fluidigm Corporation, Streck Inc., SeraCare, Enzo Biochem Inc., Epigenomics AG, Veridex LLC
How are evolving market trends shaping rare biomarkers specimen collection and stabilization Strategies?
Key players in the unique biomarker specimen collection and stabilization sector are concentrating on creating groundbreaking solutions like a pre-analytical platform to streamline the process of preparing plasma and cell samples for various types of liquid biopsy. The pre-analytical platform delivers automated fresh sample preparation at the time of blood collection and doesn’t require skilled professionals or special tubes, therefore ensuring the preservation of sample integrity. For instance, in May 2022, Tethis S.p.A, a biotech firm based in Italy, introduced See.d, the first-ever fully automated, standardized pre-analytical platform. This platform boasts of features such as accurate sample handling, efficient plasma separation for cellular fractions, and securing white blood cells on SmartBioSurface slides. The platform also has a quality control scoring system that allows for an objective evaluation of sample stability. Through this, it allows systematic scoring of proteomics and metabolomics data sets, which help to ascertain the stability of plasma and serum samples.
Unlock exclusive market insights – purchase your research report now for a swift delivery!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=15913
Which regions are most influential in expanding the rare biomarkers specimen collection and stabilization market?
North America was the largest region in the rare biomarkers specimen collection and stabilization market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the rare biomarkers specimen collection and stabilization market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
Browse Through More Similar Reports By The Business Research Company:
Non-Alcoholic Steatohepatitis Biomarkers Global Market Report 2024
Biomarkers Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/biomarkers-global-market-report
Cardiac Biomarkers Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/cardiac-biomarkers-global-market-report
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
